Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
oncology drug
Advertisement
MEKanistic Clears FDA IND for MTX-531 Cancer Trial
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
BeOne Medicines Wins FDA Approval for BEQALZI in Mantle Cell Lymphoma
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
Abbisko Pimicotinib NDA Progress Advances TGCT Therapy
Shanghai, China – April 22, 2026 In a major milestone for rare tumor therapeutics, Abbisko Therapeutics has announced significant...
Advertisements
Frontier Licenses p53 Cancer Drug FMC-220 to LG Chem
BOSTON & SOUTH SAN FRANCISCO, Calif., USA, April 1, 2026 Frontier Medicines has announced an exclusive global licensing agreement...
Abbisko Irpagratinib Gains EMA Orphan Drug Status
SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...
Eisai Nuvation Taletrectinib EMA MAA Validation
Tokyo & New York – March 27, 2026 Eisai and Nuvation Bio announced that the European Medicines Agency (EMA)...
CStone CS2009 Shows Strong Phase I/II Cancer Data
Suzhou, China – March 26, 2026 CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong...
Foresee Wins FDA Nod for CAMCEVI ETM Three-Month Injectable
TAIPEI, August 28, 2025 — Foresee Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the...
Advertisement
